SS
UNCY icon

SBI Securities’s Unicycive Therapeutics UNCY Stock Holding History

SBI Securities’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.67K Sell
557
-1
-0.2% -$7 ﹤0.01% 2162
2025
Q4 		$3.22K Sell
558
-2
-0.4% -$11 ﹤0.01% 2209
2025
Q3 		$2.44K Buy
560
+7
+1% +$31 ﹤0.01% 2347
2025
Q2 		$2.64K Buy
553
+550
+18,333% +$3.4K ﹤0.01% 2274
2025
Q1 		$14 Sell
3
-2
-40% -$12 ﹤0.01% 3922
2024
Q4 		$39 Buy
+5
New +$28 ﹤0.01% 3689

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SBI Securities's UNCY Position: Q1 2026 in Review

SBI Securities reduced its Unicycive Therapeutics (UNCY) stake by 0.18% in Q1 2026, selling an estimated $7 and leaving 557 shares worth $3.67K. The position accounts for ﹤0.01% of the portfolio, ranked #2162.

SBI Securities first reported a position in UNCY in Q4 2024 and has held it in 6 quarters since. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • SBI Securities held 557 shares of Unicycive Therapeutics worth $3.67K as of Q1 2026.
  • SBI Securities sold 1 Unicycive Therapeutics share in Q1 2026, an estimated $7.
  • Unicycive Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #2162 holding.
  • SBI Securities first reported a position in Unicycive Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.